Form D · Biotechnology
Hemostemix Inc.
Blackfalds, A0 · CIK 0001716567
Offering snapshot reported Sep 14, 2017 · SEC filing
- Reported sold
- $0 Offering amount: $132K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 25, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 14, 2017 | Initial | $0 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-294665
Source: Form D, filed Sep 14, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Berman | Executive |
| Don Friesen | Director |
| Angus Jenkins | Director |
| Kyle Makofka | Executive |
| Ina Sarel | Executive |
| David L. Wood | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Bay 1, 5220 Duncan Avenue, Po Box 10
Blackfalds, A0, T0M 0J0
Blackfalds, A0, T0M 0J0